Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 3/20 | 0.64 |
| ▸ | PTK2 | Q05397 | 15/20 | 0.64 |
| ▸ | CDK4 | P11802 | 3/20 | 0.52 |
| ▸ | CDK1 | P06493 | 2/20 | 0.52 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.52 |
| ▸ | CCND1 | P24385 | 2/20 | 0.52 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.52 |
| ▸ | CDK2 | P24941 | 2/20 | 0.52 |
| ▸ | JAK3 | P52333 | 2/20 | 0.51 |
| ▸ | LCK | P06239 | 1/20 | 0.51 |
| ▸ | FYN | P06241 | 1/20 | 0.51 |
| ▸ | FES | P07332 | 1/20 | 0.51 |
| ▸ | RET | P07949 | 1/20 | 0.51 |
| ▸ | ROS1 | P08922 | 1/20 | 0.51 |
| ▸ | SRC | P12931 | 1/20 | 0.51 |
| ▸ | JAK1 | P23458 | 1/20 | 0.51 |
| ▸ | TYK2 | P29597 | 1/20 | 0.51 |
| ▸ | EPHB1 | P54762 | 1/20 | 0.51 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.51 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29523145 | 1.00 | JAK2 (0.64) | JAK2PTK2CDK4CDK1CCNB1 | |
| SCHEMBL29523173 | 0.90 | JAK2 (0.64) | JAK2PTK2CDK4CDK1CCNB1 | |
| SCHEMBL1674317 | 0.90 | JAK2 (0.64) | JAK2PTK2CDK4CDK1CCNB1 | |
| SCHEMBL29523430 | 0.89 | PTK2 (0.59) | JAK2PTK2CDK4JAK3LCK | |
| SCHEMBL1674059 | 0.89 | PTK2 (0.59) | JAK2PTK2CDK4JAK3LCK | |
| SCHEMBL14853047 | 0.89 | PTK2 (0.67) | JAK2PTK2CDK4JAK3LCK | |
| SCHEMBL1674303 | 0.85 | PTK2 (0.65) | JAK2PTK2CDK4JAK3LCK | |
| SCHEMBL29523374 | 0.85 | PTK2 (0.65) | JAK2PTK2CDK4JAK3LCK | |
| SCHEMBL1674300 | 0.83 | PTK2 (0.62) | JAK2PTK2CDK4JAK3LCK | |
| SCHEMBL29523465 | 0.83 | PTK2 (0.62) | JAK2PTK2CDK4JAK3LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12383558-B2 | Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections | EMORY UNIVERSITY (US) | 2025-08-12 | — | — | US | claimed |
| EP-4556010-A2 | JAK INHIBITORS FOR USE IN THE PREVENTION OR TREATMENT OF A VIRAL DISEASE CAUSED BY A CORONAVIRIDAE | Emory University (US) | 2025-05-21 | — | — | EP | claimed |
| US-20240415838-A1 | USE OF TREM-1 INHIBITORS FOR TREATMENT, ELIMINATION AND ERADICATION OF HIV-1 INFECTION | UNIV EMORY (US) | 2024-12-19 | — | — | US | claimed |
| US-20240173322-A1 | ANTIVIRAL JAK INHIBITORS USEFUL IN TREATING OR PREVENTING RETROVIRAL AND OTHER VIRAL INFECTIONS | UNIV EMORY (US) | 2024-05-30 | — | — | US | claimed |
| US-11744831-B2 | Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections | EMORY UNIVERSITY (US) | 2023-09-05 | — | — | US | claimed |
| US-20220313696-A9 | USE OF TREM-1 INHIBITORS FOR TREATMENT, ELIMINATION AND ERADICATION OF HIV-1 INFECTION | UNIV EMORY (US) | 2022-10-06 | — | — | US | claimed |
| US-20220110939-A1 | ANTIVIRAL JAK INHIBITORS USEFUL IN TREATING OR PREVENTING RETROVIRAL AND OTHER VIRAL INFECTIONS | UNIV EMORY (US) | 2022-04-14 | — | — | US | claimed |
| US-20220040185-A1 | USE OF TREM-1 INHIBITORS FOR TREATMENT, ELIMINATION AND ERADICATION OF HIV-1 INFECTION | UNIV EMORY (US) | 2022-02-10 | — | — | US | claimed |
| US-11065254-B2 | Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (US) | 2021-07-20 | — | — | US | claimed |
| US-11052090-B2 | Use of TREM-1 inhibitors for treatment, elimination and eradication of HIV-1 infection | EMORY UNIVERSITY (US) | 2021-07-06 | — | — | US | claimed |
| US-9089574-B2 | Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections | EMORY UNIVERSITY (US) | 2015-07-28 | — | — | US | claimed |
| US-20140328793-A1 | ANTIVIRAL JAK INHIBITORS USEFUL IN TREATING OR PREVENTING RETROVIRAL AND OTHER VIRAL INFECTIONS | EMORY UNIVERSITY (US) | 2014-11-06 | — | — | US | claimed |
| EP-2785184-A1 | ANTIVIRAL JAK INHIBITORS USEFUL IN TREATING OR PREVENTING RETROVIRAL AND OTHER VIRAL INFECTIONS | Emory University (US) | 2014-10-08 | — | — | EP | claimed |
| US-8765755-B2 | N-containing heterocyclic compounds | YM BIOSCIENCES AUSTRALIA PTY LTD. (AU) | 2014-07-01 | — | — | US | claimed |
| WO-2013082476-A1 | ANTIVIRAL JAK INHIBITORS USEFUL IN TREATING OR PREVENTING RETROVIRAL AND OTHER VIRAL INFECTIONS | EMORY UNIVERSITY (US) | 2013-06-06 | — | — | WO | claimed |
| US-20130090336-A1 | N-CONTAINING HETEROCYCLIC COMPOUNDS | YM BIOSCIENCES AUSTRALIA PTY LTD (AU) | 2013-04-11 | — | — | US | claimed |
| US-8354408-B2 | N-containing heterocyclic compounds | YM BIOSCIENCES AUSTRALIA PTY LTD (AU) | 2013-01-15 | — | — | US | claimed |
| US-20110092499-A1 | N-CONTAINING HETEROCYCLIC COMPOUNDS | YM BIOSCIENCES AUSTRALIA PTY LTD (AU) | 2011-04-21 | — | — | US | claimed |
| EP-2215094-A1 | N-CONTAINING HETEROCYCLIC COMPOUNDS | YM BioSciences Australia Pty Ltd (AU) | 2010-08-11 | — | — | EP | claimed |
| WO-2009062258-A1 | N-CONTAINING HETEROCYCLIC COMPOUNDS | CYTOPIA RESEARCH PTY LTD (AU) | 2009-05-22 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140328793-A1 | ANTIVIRAL JAK INHIBITORS USEFUL IN TREATING OR PREVENTING RETROVIRAL AND OTHER VIRAL INFECTIONS | JAK1, JAK3, PNP | JAK2 4/4885PTK2 1835/4885CDK4 48/4885 |
| US-11744831-B2 | Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections | JAK1, JAK3, PNP | JAK2 4/4885PTK2 2303/4885CDK4 198/4885 |
| US-20220110939-A1 | ANTIVIRAL JAK INHIBITORS USEFUL IN TREATING OR PREVENTING RETROVIRAL AND OTHER VIRAL INFECTIONS | JAK1, JAK3, PNP | JAK2 4/4885PTK2 2303/4885CDK4 198/4885 |
| US-20130090336-A1 | N-CONTAINING HETEROCYCLIC COMPOUNDS | JAK2, JAK3, JAK1 | JAK2 1/4885PTK2 220/4885CDK4 130/4885 |
| US-20240415838-A1 | USE OF TREM-1 INHIBITORS FOR TREATMENT, ELIMINATION AND ERADICATION OF HIV-1 INFECTION | MERTK, PNP, HAVCR2 | JAK2 277/4885PTK2 418/4885CDK4 1097/4885 |
| US-20240173322-A1 | ANTIVIRAL JAK INHIBITORS USEFUL IN TREATING OR PREVENTING RETROVIRAL AND OTHER VIRAL INFECTIONS | JAK1, JAK3, PNP | JAK2 4/4885PTK2 1835/4885CDK4 48/4885 |
| US-20110092499-A1 | N-CONTAINING HETEROCYCLIC COMPOUNDS | JAK2, JAK3, JAK1 | JAK2 1/4885PTK2 220/4885CDK4 130/4885 |
| US-12383558-B2 | Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections | JAK1, JAK3, PNP | JAK2 4/4885PTK2 1835/4885CDK4 48/4885 |
| US-20220040185-A1 | USE OF TREM-1 INHIBITORS FOR TREATMENT, ELIMINATION AND ERADICATION OF HIV-1 INFECTION | MERTK, PNP, HAVCR2 | JAK2 277/4885PTK2 418/4885CDK4 1097/4885 |
| US-11052090-B2 | Use of TREM-1 inhibitors for treatment, elimination and eradication of HIV-1 infection | MERTK, PNP, HAVCR2 | JAK2 277/4885PTK2 418/4885CDK4 1097/4885 |
| US-20220313696-A9 | USE OF TREM-1 INHIBITORS FOR TREATMENT, ELIMINATION AND ERADICATION OF HIV-1 INFECTION | MERTK, PNP, HAVCR2 | JAK2 277/4885PTK2 418/4885CDK4 1097/4885 |
| US-11065254-B2 | Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections | JAK1, JAK3, PNP | JAK2 4/4885PTK2 1835/4885CDK4 48/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.